Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC).
Cox-2, Survivin and Bcl-2 are frequently overexpressed in numerous types of cancers. They are known to be the important regulators of apoptosis. This study was designed to investigate the correlation between the clinical characteristics and the expression of Cox-2, Survivin and Bcl-2 in hepatocellular carcinoma. A total of 63 postoperative hepatocellular carcinoma (HCC) samples, 10 adjacent non-tumor samples and 10 normal liver samples were immunochemically detected for the expression of Cox-2, Survivin and Bcl-2. A median follow-up of 4 years for the 63 HCC patients was conducted. Univariate tests and multivariate Cox regression were performed for statistical analysis. The Kaplan-Meier method was used to analyze the survival. Positive expression of Cox-2 (84.3%) and Survivin (77.8%) was detected significantly more frequently in the HCC samples than in the normal liver tissues (30% and 0, respectively). Bcl-2 was highly expressed in the adjacent non-tumor tissue. Cox-2 was positively correlative to Survivin. Survivin and Bcl-2 were significantly associated with the pathological grade of HCC (P<0.05). Expression of both Cox-2 and Survivin was significantly associated with the poor overall survival (OS) (P=0.0141, P=0.0039). Furthermore, multivariate analysis confirmed the independent prognostic value of Survivin expression, along with tumor size and hepatic function. Cox-2 and Survivin were highly expressed in the HCC tissue. Survivin and Bcl-2 were significantly associated with the pathological grade of HCC. The expression of Survivin was an independent prognostic factor for HCC after a hepatectomy. Treatment that inhibits Survivin may be a promising targeted approach in HCC.
Yang
Yu
Y
Department of Medical Oncology, Cancer Center of West China Hospital, Sichuan University, Chengdu, China.
Zhu
Jiang
J
Gou
Hongfeng
H
Cao
Dan
D
Jiang
Ming
M
Hou
Mei
M
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000401:mortality; D051546:Cyclooxygenase 2 / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000096:biosynthesis*; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000378:metabolism* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis*; D000077022:Survivin
C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D000077022:Survivin; D051546:Cyclooxygenase 2
Clin Cancer Res. 2004 May 1;10(9):3117-23
15131052
Clin Cancer Res. 2001 Apr;7(4):861-7
11309334
World J Gastroenterol. 2003 Jul;9(7):1421-6
12854133
Anticancer Res. 2007 Jan-Feb;27(1A):219-22
17352236
J Clin Oncol. 2008 Dec 20;26(36):5845-8
19029408
Histopathology. 1999 Oct;35(4):360-7
10564391
Gynecol Oncol. 2004 Mar;92(3):806-12
14984945
Hepatol Res. 2002 Jul;23(3):185-195
12076714
Pathol Res Pract. 2008;204(4):241-9
18171606
Int J Cancer. 2005 Aug 10;116(1):100-4
15761870
Cancer Control. 2002 Mar-Apr;9(2 Suppl):28-35
11965228
Br J Cancer. 2006 Jan 30;94(2):253-8
16421596
Int J Cancer. 2001 Oct 15;94(2):153-6
11668491
Hepatology. 1999 Mar;29(3):688-96
10051469
Clin Cancer Res. 2001 May;7(5):1410-8
11350912
Zhonghua Fu Chan Ke Za Zhi. 2001 Sep;36(9):546-8
11769670
Cancer Res. 1998 Jan 15;58(2):362-6
9443418
Cancer. 2001 Jun 1;91(11):2026-32
11391581
Ann Oncol. 2006 Apr;17(4):597-604
16403812
Cancer Res. 2005 May 1;65(9):3531-4
15867343
Cancer Res. 1998 Oct 1;58(19):4245-9
9766645
Hum Pathol. 2001 Jan;32(1):119-25
11172305
J Clin Oncol. 2005 May 1;23(13):2892-9
15860847
World J Gastroenterol. 2005 Apr 7;11(13):1896-902
15800977
J Clin Pathol. 2009 Aug;62(8):690-3
19638539
Cancer Res. 1998 May 1;58(9):1808-12
9581817
FASEB J. 2004 Jan;18(1):206-8
14597555
J Clin Oncol. 2009 Jun 20;27(18):3027-35
19470923
J Cell Biochem. 1996 Jan;60(1):23-32
8825412
Mol Cancer Ther. 2004 Mar;3(3):299-307
15026550
Clin Cancer Res. 1999 Dec;5(12):4005-12
10632332
Indian J Med Microbiol. 2007 Oct;25(4):323-9
18087079
J Hepatol. 2001 Sep;35(3):421-30
11592607
Clin Cancer Res. 2005 May 15;11(10):3784-9
15897577
Int J Oncol. 2002 Aug;21(2):315-20
12118327
Mol Cancer Ther. 2006 Mar;5(3):693-703
16546984
Lab Invest. 1999 Sep;79(9):1121-6
10496530